Please login to the form below

Not currently logged in
Email:
Password:

Hunter syndrome

This page shows the latest Hunter syndrome news and features for those working in and with pharma, biotech and healthcare.

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

It’s scheduled for regulatory approval in 2020. TAK-609 for Hunter syndrome:TAK-609 (formerly  SHP609) is a new intrathecal formulation of Takeda’s existing intravenous Hunter syndrome therapy Elaprase ... including Dravet syndrome, and is tipped

Latest news

More from news
Approximately 3 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The phase 1/2 CHAMPIONS study did show that a single injection of SB-913 for the rare genetic disease mucopolysaccharidosis type II (MPS II) or Hunter syndrome was able to

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    360. Sigma-Tau/ Jazz Pharmaceuticals. Regaining rights. Defibrotide for severe hepatic veno-occlusive disease (approved EU/ NDA US)    . 250. ArmaGen/ Shire   . Licence, collaboration   . AGT-182, enzyme replacement therapy for Hunter

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • TVF Communications shortlisted for two awards at PMEA 2016!

    For both target diseases, Hunter Syndrome(MPS II) and Hidradenitis Suppurativa (HS), a timely diagnosis is imperative, as the early symptoms are often mistaken for far more common and far less ... refer to a geneticist if the syndrome is suspected.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics